OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 626 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR 2023 Highlights in Treating Genitourinary Cancers: Expert Perspectives January 24, 2024 Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of... September 17, 2025 Reunión anual de la ASCO de 2022: Gasto en servicios sociales... May 26, 2022 Liquid Biopsies on the Horizon for Children with Solid Cancers April 11, 2023 Load more HOT NEWS Sofi Leota Was Diagnosed With Breast Cancer At 23. Two Years... Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma Abnormal Results from Prenatal Blood Test Could Point to Cancer in... Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL...
